Welcome to our dedicated page for Covista SEC filings (Ticker: CVSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Covista Inc. filings document current reports on operating results, academic performance, investor communications and strategic progress for its healthcare education portfolio. Recent Form 8-K records furnish quarterly results releases, enrollment metrics, revenue and earnings measures, fiscal guidance, share repurchase activity, debt refinancing references and institutional updates for Chamberlain and Walden.
The company's Regulation FD disclosures also include investor newsletters describing milestones, partnerships, workforce-related initiatives and operational progress. Covista's filing record identifies public-company disclosure themes tied to results of operations, capital allocation, governance signatories, cautionary forward-looking statements and the company's current identity as a NYSE-listed healthcare educator.
Covista Inc. (CVSA) filed an initial ownership report for Emily C. Chiu, who is identified as a director of the company. The Form 3 shows no reportable transactions or holdings of Covista securities at the time of this filing, based on the provided data.
Covista Inc.’s Chairman & CEO Stephen W. Beard reported a sale of 3,545 shares of Common Stock on August 11, 2026 at a weighted average price of $130.345 per share, executed in multiple trades between $130.005 and $131.343. The sale was carried out under a pre-established Rule 10b5-1 trading plan adopted on December 10, 2025 pursuant to Covista’s insider trading policies, which state that no discretionary trades are permitted absent a hardship exception. Following this transaction, Beard held 415,197 shares directly.
Covista Inc. (CVSA) has a planned sale of Covista common stock by the Stephen Wayne Beard Trust u/a/d 09/03/2015, with Mr. Stephen W. Beard Jr. as trustee. The trust has engaged Goldman Sachs & Co. LLC, 200 West Street, New York, as broker to sell 3,545 shares of Covista common stock on or after 08/11/2026 on the NYSE. These shares were acquired on 09/08/2025 as compensation in the form of Restricted Stock Units.
Over the past three months, the trust has already sold Covista common stock in three transactions: 2,762 shares on 06/10/2026 for $359,443.37, 2,529 shares on 06/11/2026 for $330,754.51, and 5,291 shares on 07/13/2026 for $702,399.30.
Covista Inc. Chief Financial Officer Robert J. Phelan reported the sale of 2,186 shares of common stock on 2026-08-07 at a weighted average price of $135.15 per share, executed under a pre-established Rule 10b5-1 trading plan. Following this transaction, he directly holds 48,306 shares of Covista common stock.
Covista Inc. executive Douglas G. Beck (SVP, General Counsel, Corporate Secretary & ISS) reported a sale of 4,526 shares of Covista common stock on August 7, 2026 at a weighted average price of $135.81 per share. After this transaction, he directly holds 28,544 shares. The sale was executed under a Rule 10b5-1 trading plan adopted on December 11, 2025, with trades carried out in pre-scheduled increments and prices ranging from $135.00 to $136.785 per share. Footnotes state that Covista policy does not permit discretionary trades by the reporting person, and all sales must occur pursuant to a pre-established Rule 10b5-1 plan absent a hardship exception.
Covista Inc., a Delaware corporation based in Chicago, operates as America’s largest healthcare educator, serving 100,000 students and an alumni network of 400,000 across five accredited institutions: Chamberlain, Walden, AUC, RUSM, and RUSVM. It reports three segments: Chamberlain, Walden, and Medical and Veterinary.
The model relies heavily on U.S. federal student aid; Covista’s Title IV institutions collectively receive 78% of revenue from Title IV programs and are subject to extensive regulation under the HEA, OBBBA, and related ED rules, including Do No Harm and Gainful Employment frameworks. A fiscal 2022 composite financial-responsibility score of 0.2 led to provisional certification, heightened cash monitoring, and $202.6 million in surety-backed letters of credit, plus $80.0 million of state surety bonds.
As of December 31, 2025, non‑affiliate equity market value was $3,488,231,961, and as of July 31, 2026, shares outstanding were 34,038,82078% in 2025, and cohort default rates for all institutions were 0.0% for the 2020–2022 cohorts. Covista employs 10,680 people worldwide and details extensive regulatory, financial-aid, and litigation-related risk factors that could materially affect operations.
Covista Inc. reported higher fourth-quarter and fiscal 2026 results for the year ended June 30, 2026, and stated it exceeded its fiscal 2026 and long-term financial targets while completing its three-year Growth with Purpose strategy. Full-year revenue from continuing operations was $1,954,085 (in thousands), up 9.3% year over year, with Q4 revenue of $501,382 (in thousands), up 9.7%, and total Q4 enrollment up 8.4%.
Net income was $251,566 (in thousands) and diluted EPS was $7.04. Adjusted EPS was $8.25, a 23.7% increase from $6.67. Adjusted EBITDA rose to $521,736 (in thousands), a 13.5% increase. Net cash provided by operating activities from continuing operations reached $470,796 (in thousands). Net leverage was 0.5x, based on net debt of $266,684 (in thousands).
By segment, Chamberlain grew revenue 3.4% for the year, Walden 16.1%, and Medical and Veterinary 8.1%. Walden’s total students increased 14.0%, and Medical and Veterinary students grew 7.3%. Chamberlain’s full-year operating income declined 6.5%. Covista launched its next strategy phase, Purpose at Scale, and initiated fiscal 2027 guidance.
FMR LLC filed an amended beneficial ownership report for COVISTA INC common stock. FMR LLC reports beneficial ownership of 3,218,202.84 shares, representing 9.5% of the class, with sole dispositive power over all such shares and no shared voting or dispositive power.
Abigail P. Johnson is reported as having sole dispositive power over the same 3,218,202.84 shares, also equating to 9.5% of the outstanding common stock, with no sole or shared voting power. One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the class.
Covista Inc. has appointed Ms. Emily Chiu and Ms. Leslie Storms as independent members of its Board of Directors, effective August 17, 2026. Both will stand for re-election at Covista’s 2026 annual meeting of stockholders, and future committee assignments will be determined by the Board.
Each new director will receive a prorated grant of restricted stock units with a grant date fair value of approximately $32,986.00 on August 17, 2026, an additional equity retainer restricted stock unit grant valued at $150,000.00 immediately following the annual meeting, and annual cash compensation of $85,000.00 paid quarterly. Covista states there are no appointment arrangements or related-party transactions requiring disclosure, and the Board size will increase from ten to twelve members effective August 17, 2026.
Manning Amelia reported acquisition or exercise transactions in this Form 4 filing.
Covista Inc. reported that Amelia Manning, President of Chamberlain University, received a grant of 4,317 shares of common stock as a compensation award. The award, structured as restricted stock units convertible into common shares on a one-for-one basis, was valued at $115.82 per share for reporting purposes.
The restricted stock units vest in two equal installments beginning on July 15, 2027. Following this grant, Manning holds 4,317 shares directly, reflecting this new award and indicating no additional holdings reported in this filing.